The VDR gene FokI polymorphism and ovarian cancer risk

Tumor Biology

Volumn 34, Issue 6, 2013, Pages 3309-3316

  Xu, Hui ^a   Li, Su ^a   Qiu, Jian Qing ^a   Gao, Xiao Lin ^a   Zhang, Ping ^a   Yang, Yong Xia ^a  

^a THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

Author keywords

FokI; Meta analysis; Ovarian cancer; Polymorphism; Vitamin D receptor

Indexed keywords

VITAMIN D RECEPTOR;

AFRICAN AMERICAN; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CAUCASIAN; DISEASE ASSOCIATION; ETHNIC DIFFERENCE; FOKI GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC VARIABILITY; GENOTYPE; HUMAN; ONCOGENE; OVARY CANCER; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; RECESSIVE GENE; RISK ASSESSMENT; SYSTEMATIC REVIEW;

EID: 84891440889     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0826-8     Document Type: Article

References (48)

1. Permuth-Wey J, Sellers TA. Epidemiology of ovarian cancer. Methods Mol Biol. 2009;472:413-37.
2. Westhoff C. Ovarian cancer. Annu Rev Public Health. 1996;17:85-96.
3. Cramer DW. The epidemiology of endometrial and ovarian cancer. Hematol Oncol Clin N Am. 2012;26:1-12.
4. Worley MJ, Welch WR, Berkowitz RS, Ng SW. Endometriosis-associated ovarian cancer: a review of pathogenesis. Int J Mol Sci. 2013;14:5367-79.
5. Cetin I, Cozzi V, Antonazzo P. Infertility as a cancer risk factor - a review. Placenta. 2008;29 Suppl B:169-77.
6. Shen N, Weiderpass E, Antilla A, Goldberg MS, Vasama-Neuvonen KM, Boffetta P, et al. Epidemiology of occupational and environmental risk factors related to ovarian cancer. Scand J Work Environ Health. 1998;24:175-82.
7. Shields T, Gridley G, Moradi T, Adami J, Plato N, Dosemeci M. Occupational exposures and the risk of ovarian cancer in Sweden. Am J Ind Med. 2002;42:200-13.
8. Bolton KL, Ganda C, Berchuck A, Pharaoh PD, Gayther SA. Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the Ovarian Cancer Association Consortium (OCAC). J Intern Med. 2012;271:366-78.
9. Vuolo L, Di Somma C, Faggiano A, Colao A. Vitamin D and cancer. Front Endocrinol (Lausanne). 2012;3:58.
10. Trump DL, Deeb KK, Johnson CS. Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy. Cancer J. 2010;16:1-9.
11. Thomas MG, Tebbutt S, Williamson RC. Vitamin D and its metabolites inhibit cell proliferation in human rectal mucosa and a colon cancer cell line. Gut. 1992;33:1660-3.
12. Bai YH, Lu H, Hong D, Lin CC, Yu Z, Chen BC. Vitamin D receptor gene polymorphisms and colorectal cancer risk: a systematic meta-analysis. World J Gastroenterol. 2012;18:1672-9.
13. Raimondi S, Johansson H, Maisonneuve P, Gandini S. Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis. 2009;30:1170-80.
14. Falleti E, Bitetto D, Fabris C, Cussigh A, Fontanini E, Fornasiere E, et al. Vitamin D receptor gene polymorphisms and hepatocellular carcinoma in alcoholic cirrhosis. World J Gastroenterol. 2010;16:3016-24.
15. McKay JD, McCullough ML, Ziegler RG, Kraft P, Saltzman BS, Riboli E, et al. Vitamin D receptor polymorphisms and breast cancer risk: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev. 2009;18:297-305.
16. Li H, Stampfer MJ, Hollis JB, Mucci LA, Gaziano JM, Hunter D, et al. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med. 2007;4:e103.
17. Cochran WG. The comparison of percentages in matched samples. Biometrika. 1950;37:256-66.
18. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60.
19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88.
20. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-48.
21. Lurie G, Wilkens LR, Thompson PJ, McDuffie KE, Carney ME, Terada KY, et al. Vitamin D receptor gene polymorphisms and epithelial ovarian cancer risk. Cancer Epidemiol Biomarkers Prev. 2007;16:2566-71.
22. Clendenen TV, Arslan AA, Koenig KL, Enquist K, Wirgin I, Agren A, et al. Vitamin D receptor polymorphisms and risk of epithelial ovarian cancer. Cancer Lett. 2008;260:209-15.
23. Tworoger SS, Gates MA, Lee IM, Buring JE, Titus-Ernstoff L, Cramer D, et al. Polymorphisms in the vitamin D receptor and risk of ovarian cancer in four studies. Cancer Res. 2009;69:1885-91.
24. Lurie G, Wilkens LR, Thompson PJ, Carney ME, Palmieri RT, Pharoah PD, et al. Vitamin D receptor rs2228570 polymorphism and invasive ovarian carcinoma risk: pooled analysis in five studies within the Ovarian Cancer Association Consortium. Int J Cancer. 2011;128:936-43.
25. Grant DJ, Hoyo C, Akushevich L, Iversen ES, Whitaker R, Marks J, et al. Vitamin D receptor (VDR) polymorphisms and risk of ovarian cancer in Caucasian and African American women. Gynecol Oncol. 2012;129:173-8.
26. Mostowska A, Sajdak S, Pawlik P, Lianeri M, Jagodzinski PP. Vitamin D receptor gene BsmI and FokI polymorphisms in relation to ovarian cancer risk in the Polish population. Genet Test Mol Biomark. 2013;17:183-7.
27. Miyamoto K, Kesterson RA, Yamamoto H, Taketani Y, Nishiwaki E, Tatsumi S, et al. Structural organization of the human vitamin D receptor chromosomal gene and its promoter. Mol Endocrinol. 1997;11:1165-79.
28. Whitfield GK, Remus LS, Jurutka PW, Zitzer H, Oza AK, Dang HT, et al. Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene. Mol Cell Endocrinol. 2001;177:145-59.
29. Ahonen MH, Zhuang YH, Aine R, Ylikomi T, Tuohimaa P. Androgen receptor and vitamin D receptor in human ovarian cancer: growth stimulation and inhibition by ligands. Int J Cancer. 2000;86:40-6.
30. Kocabas A, Karaguzel G, Imir N, Yavuzer U, Akcurin S. Effects of vitamin D receptor gene polymorphisms on susceptibility to disease and bone mineral density in Turkish patients with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2010;23:1289-97.
31. Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA, Van Leeuwen JP. Genetics and biology of vitamin D receptor polymorphisms. Gene. 2004;338:143-56.
32. Uitterlinden AG, Fang Y, van Meurs JB, van Leeuwen H, Pols HA. Vitamin D receptor gene polymorphisms in relation to vitamin D related disease states. J Steroid Biochem Mol Biol. 2004;89-90:187-93.
33. Ralston SH. The genetics of osteoporosis. QJM. 1997;90:247-51.
34. Kostner K, Denzer N, Muller CS, Klein R, Tilgen W, Reichrath J. The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer Res. 2009;29:3511-36.
35. Bouillon R, Carmeliet G, Verlinden L, van Etten E, Verstuyf A, Luderer HF, et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev. 2008;29:726-76.
36. Timms PM, Mannan N, Hitman GA, Noonan K, Mills PG, Syndercombe-Court D, et al. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? QJM. 2002;95:787-96.
37. Holick MF. Vitamin D: its role in cancer prevention and treatment. Prog Biophys Mol Biol. 2006;92:49-59.
38. Cramer DW. Epidemiologic aspects of early menopause and ovarian cancer. Ann N Y Acad Sci. 1990;592:363-75. discussion 90-4.
39. Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst. 1983;71:717-21.
40. Li Y, Hao YL, Kang S, Zhou RM, Wang N, Qi BL. Genetic polymorphisms in the Fas and FasL genes are associated with epithelial ovarian cancer risk and clinical outcomes. Gynecol Oncol. 2013;128:584-9.
41. Romanowicz-Makowska H, Smolarz B, Samulak D, Michalska M, Lewy J, Burzynski M, et al. A single nucleotide polymorphism in the 5′ untranslated region of RAD51 and ovarian cancer risk in Polish women. Eur J Gynaecol Oncol. 2012;33:406-10.
42. Oliveira C, Lourenco GJ, Sagarra RA, Derchain SF, Segalla JG, Lima CS. Polymorphisms of glutathione S-transferase Mu 1 (GSTM1), Theta 1 (GSTT1), and Pi 1 (GSTP1) genes and epithelial ovarian cancer risk. Dis Markers. 2012;33:155-9.
43. Fang Y, van Meurs JB, d'Alesio A, Jhamai M, Zhao H, Rivadeneira F, et al. Promoter and 3′-untranslated-region haplotypes in the vitamin d receptor gene predispose to osteoporotic fracture: the Rotterdam study. Am J Hum Genet. 2005;77:807-23.
44. Jurutka PW, Remus LS, Whitfield GK, Thompson PD, Hsieh JC, Zitzer H, et al. The polymorphic N terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interaction with transcription factor IIB. Mol Endocrinol. 2000;14:401-20.
45. Jurutka PW, Whitfield GK, Hsieh JC, Thompson PD, Haussler CA, Haussler MR. Molecular nature of the vitamin D receptor and its role in regulation of gene expression. Rev Endocr Metab Disord. 2001;2:203-16.
46. Gross C, Krishnan AV, Malloy PJ, Eccleshall TR, Zhao XY, Feldman D. The vitamin D receptor gene start codon polymorphism: a functional analysis of FokI variants. J Bone Miner Res. 1998;13:1691-9.
47. Guy M, Lowe LC, Bretherton-Watt D, Mansi JL, Peckitt C, Bliss J, et al. Vitamin D receptor gene polymorphisms and breast cancer risk. Clin Cancer Res. 2004;10:5472-81.
48. Du XL, Sun CC, Milam MR, Bodurka DC, Fang S. Ethnic differences in socioeconomic status, diagnosis, treatment, and survival among older women with epithelial ovarian cancer. Int J Gynecol Cancer. 2008;18:660-9.